AFMD News and Press, Affimed N.V. From 10/29/21

HEIDELBERG, Germany, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it will release third quarter 2021 results on Wednesday, November 10, 202...

Biotech is having a moment right now. Despite the industry's numerous successes in developing treatments for scores of once undruggable indications, investors have backed away from this area of the market this year. The bellwether SPDR S&P Biotech ETF is down by almost 12% year to d...

Affimed reported mixed Q2 earnings that revealed more milestone payments from their partnerships. In addition, Affimed reported a healthy cash position that is expected to last into 2H of 2022. Affimed continues to move their wholly-owned and partnered pipeline programs. However, 2022...

HEIDELBERG, Germany, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that three abstracts with preclinical data of its innate cell engagers have be...

The following slide deck was published by Affimed N.V. in conjunction with this event. For further details see: Affimed N.V. (AFMD) Investor Presentation - Slideshow

Image source: The Motley Fool. Affimed NV (NasdaqGM:AFMD) (NASDAQ: AFMD) Q2 2021 Earnings Call Sep 8, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Affimed NV (NasdaqGM:AFMD) (AFMD) Q2 2021 Earnings Call Transcrip...

Affimed N.V. (AFMD) Q2 2021 Earnings Conference Call September 8, 2021 08:30 ET Company Participants Alex Fudukidis - Head, Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Arndt Schottelius - Chief Scientific Officer Wolfgang Fischer - Chief Op...

AFM13 monotherapy: Enrollment is on track and expected to be completed in the first half of 2022. AFM13 combination with NK cells: All three dose escalation cohorts are fully enrolled with no dose limiting toxicities observed; additional patients are being enrolled at the highest dose...

AFMD, CASY, DLNG, GENI, KFY For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Wednesday's open

HEIDELBERG, Germany, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it will release second quarter 2021 results on Wednesday, September 8, 20...